Article

Male Childhood Cancer Survivors Face Higher Risk for Fertility Problems

Men diagnosed with cancer under age 25 far less likely to have children and more likely to take infertility drugs.

Males who have survived childhood or adolescent cancer are at a higher risk for fertility issues and are 3 times more likely to get assisted fertilization, according to a recent study.

Researchers at the University of Bergen (UiB) looked at Norwegian men born between 1965 and 1985 and were registered in compulsory national registries in Norway. The results showed men diagnosed with cancer under the age of 25 years were far less likely to have children than those who didn’t have cancer.

"These finds are important for male cancer survivors, seeing as we can identify groups at risk of having reproduction problems," said lead author Maria Winther Gunnes, PhD.

This recent data could prove to be helpful in future cancer treatments by administering treatments that affect fertility to a lesser degree. Patients could also preserve sperm before starting treatment.

The number of childhood cancer survivors has increased as a result of improved treatment options and care, with nearly 80% of pediatric cancer patients surviving the disease, the study noted.

The researchers found a reduction in paternity for male cancer survivors, especially those who had had testicular cancer, lymphoma, leukemia, bone cancer, and brain tumors. Male survivors also were less likely to get married.

However, the children of cancer survivors were not found to have an increased risk for perinatal death, congenital anomalies, increased risk of preterm birth, or low birth weight.

"It is important to be able to assure young, male cancer survivors that their illness and treatment will not have a negative impact on their own children," Gunnes said.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards